Home DM² NB Application Access

The People

Principle Investigators

  • Christine Pippy, M.D., MSc, F.R.C.P.C.
  • Jennifer Ryan, BSc.Pharm, Pharm D, ACPR
  • Valerie Price, RN CNeph(c)

Partners and Sponsors

The team at DM2 would like to thank our many partners.

  • The Province of New Brunswick - in-kind support
  • Pharmaceutical & Industry Partners
    Amgen, The Anyware Group, AstraZeneca Canada, BioVail, Bristol-Myers Squibb, Genzyme Canada, Glaxo Smith Kline, Merck, Novo Nordisk Canada Inc., Ortho-Biotech, Pfizer, Roche, Sanofi Aventis, Servier
  • Research Department Atlantic Health Sciences Corporation - Ethics Research Review
  • The core medical group - developed the treatment algorithm, project inception and is responsible for implementation

About DM² New Brunswick

The research team is working to better manage patients with type 2 diabetes by providing physicians with two new tools to treat type 2 diabetes.

Software (electronic patient management tool)
Our electronic patient management tool gives a patients' physician an easy algorithmic approach to the latest treatment guidelines pertaining to type 2 diabetes across all organ spectrums.

Multi-disciplinary clinic (rapid referral)
Participant physicians have an option to refer patients to a multi-disciplinary clinic. The clinic is made up of a core group of: a pharmacist, a nurse, a social worker, dietician and several specialists including a cardiologist, nephrologist, general internist and endocrinologist. Patients have access to the clinic in about 6 weeks after referral, greatly reducing standard wait times.

The multi-system disease management approach, if proven effective, could provide a model for future disease management strategies in New Brunswick and across North America.

  • Hypothesis: Implementation of a multi-system disease management model integrating electronic feedback for general practitioners and quick access to a multidisciplinary specialist team will demonstrate a statistically significant improvement in achieving target primary outcomes consisting of BP 130/80, Slowing of GFR decline (ml/min/yr) and HgbA1C <7%

  • Primary Outcomes: Reduction in blood pressure, reduction of GFR decline (ml/min/yr) and reduction in AIC

  • Secondary Outcomes: LDL cholesterol, development of overt nephropathy, doubling of serum creatinine or dialysis, all cause mortality, resource utilization, projected economic cost avoidance, user satisfaction (physician, patient)


Website Designed By Net Difference Logo